Health Technology · Biotechnology · NSE: AKUMS · data 2026-10-09
Akums Drugs and Pharmaceuticals Limited
Health check: Strong (7.4/10 on quality, valuation vs sector, growth and momentum).
Open full analysis — chart, results, balance sheet, red flags →Key figures
Price
₹751.85
Market cap
₹12,370 cr
P/E
39.5
P/B
—
ROE
8.0%
ROCE
9.8%
Debt / equity
0.05
Dividend yield
0.13%
1-year return
71.2%
52-week high
₹838.8
52-week low
₹409.3
Operating margin
9.1%
Growth
| Revenue (last 12 months) | ₹4,502 cr |
| Net profit (last 12 months) | ₹292 cr |
| Sales growth, 3 years (yearly) | 6.0% |
| Profit growth, 3 years (yearly) | 39.1% |
Similar companies
Anthem Biosciences Limited (ANTHEM) · Rubicon Research Limited (RUBICON) · Fermenta Biotech Ltd (FERMENTA) · Fabtech Technologies Limited (FABTECH) · Haleos Labs Ltd. (HALEOSLABS)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open AKUMS in NSE Scanner →